Orbitofrontal Cortex Stimulation for Neuropsychiatric Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropsychiatric disorders such as Major Depressive Disorder, Generalized Anxiety Disorder, Post-Traumatic Stress Disorder, Addiction, Anorexia, Obsessive-Compulsive Disorder, and Bipolar Disorder are often ineffective, with many patients not responding to existing pharmacological, cognitive behavioral, or electrophysiological interventions, and these methods often come with significant side effects and variability in patient response.
Innovation Solution
The method involves stimulating Brodmann Area 11 and/or Brodmann Area 47 of the orbitofrontal cortex using electrical stimulation, either unilaterally or bilaterally, with the option of alternating or patterning the stimulation site and frequency to treat neuropsychiatric disorders and alleviate symptoms, potentially using a closed-loop system that adjusts stimulation parameters based on real-time brain activity feedback.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological treatment with selective serotonin reuptake inhibitors is applied, then treatment coverage is provided to patients, but response rate remains low at 40-50% of patients
Solution Approach 1:
The patent employs closed-loop neurofeedback systems that monitor brain activity in real-time and adjust stimulation parameters dynamically. This feedback mechanism allows the treatment to adapt to individual patient brain states, thereby improving response reliability and reducing variability across patients with the same diagnosis.
Solution Approach 2:
The invention transitions from generalized pharmacological treatment to highly localized neural stimulation at specific brain circuits. By targeting precise neural pathways rather than administering systemic medication, the treatment achieves more consistent and reliable effects while adapting to individual circuit abnormalities.
2Reliability
If cognitive behavioral therapy is applied to prevent MDD relapse, then some effectiveness is achieved, but relapse rates remain significant at 35-50% in long-term studies
Solution Approach 1:
The patent applies neural stimulation prophylactically to high-risk brain circuits before relapse occurs. By continuously or periodically stimulating protective neural pathways in advance, the system prevents depressive episodes before they manifest, extending the duration of remission beyond what traditional therapy achieves.
Solution Approach 2:
The invention implements continuous or near-continuous neural stimulation to maintain protective brain states over the long term. This sustained intervention ensures ongoing relapse prevention without the gaps that allow symptom recurrence, addressing the duration limitation of intermittent therapies.
3Ease of manufacture
If surgical lesioning approaches are applied, then invasive treatment is provided, but full response rates are not achieved and outcomes are suboptimal
Solution Approach 1:
Instead of destroying brain tissue through lesioning, the patent inverts the approach by stimulating and activating neural circuits. This reversal transforms a destructive intervention into a constructive one, achieving better outcomes by enhancing healthy brain function rather than eliminating tissue.
Solution Approach 2:
The invention changes the fundamental parameter from irreversible tissue destruction to reversible electrical stimulation. By adjusting stimulation parameters (intensity, frequency, duration) rather than creating permanent lesions, the treatment achieves higher response rates with adjustable, titratable effects.
4Power
If electroconvulsive therapy is applied, then gross-level electrophysiological intervention is provided, but many severely affected patients experience no lasting relief and endure significant unwanted cognitive side-effects
Solution Approach 1:
The patent segments the brain into specific target circuits and applies stimulation only to those regions, rather than inducing global convulsions. This spatial segmentation concentrates therapeutic power where needed while avoiding widespread cognitive disruption in unrelated brain areas.
Solution Approach 2:
The invention uses controlled, periodic electrical stimulation at specific frequencies and durations rather than sustained high-intensity convulsions. This pulsed approach delivers therapeutic effects while allowing brain tissue to recover between stimuli, minimizing cumulative cognitive side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach has shown to effectively reduce symptoms of depression, anxiety, and chronic pain by normalizing brain activity patterns, providing a more reliable and less invasive treatment option compared to traditional methods, with potential for personalized and targeted symptom relief.
Implementation Method 1
applying electrical stimulation to the Brodmann Area 11 and/or Brodmann Area 47 via the electrode
Data Source
AI summary
The present disclosure provides a method and system for treating affective disorders such as depression and/or anxiety and/or related disorders through neuromodulatory intervention that includes brain targets within the orbitofrontal cortex (OFC). This method includes the application of electrical stimulation through an electrical signal generator device where the distal end of the device comprises at least one stimulating electrode in contact with the OFC. The treatment system includes patient selection, implantation of at least one stimulating electrode in contact with the OFC, acute or chronic electrical stimulation of the OFC, and evaluation of the effects of stimulation on clinical symptoms and status.